ArticleCirculation. Heart failure2018
Omega-3 Therapy Is Associated With Reduced Gastrointestinal Bleeding in Patients With Continuous-Flow Left Ventricular Assist Device.
Article in Circulation. Heart failure, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Gastrointestinal bleeding in recipients of left ventricular assist devices-a systematic review.Heart failure reviews · 2023Pooled it
- Hemocompatibility and biophysical interface of left ventricular assist devices and total artificial hearts.Blood · 2024Review
- Article
- Gastrointestinal bleeding on continuous-flow left ventricular assist device therapy.ESC heart failure · 2023Review
- Predictive Model for Positive Video Capsule Endoscopy in Iron Deficiency Anemia.Digestive diseases and sciences · 2023Article
- Left Ventricular Assist Devices: A Primer For the General Cardiologist.Journal of the American Heart Association · 2022Review
- Antithrombotic therapy for durable left ventricular assist devices - current strategies and future directions.Indian journal of thoracic and cardiovascular surgery · 2022Review
- Prevalence, management, and outcomes of haemorrhagic events in left ventricular assist device recipients.ESC heart failure · 2022Article
- The Antiangiogenic Activity of Flaxseed Oil Alone and Combination with Mefenamic Acid in Vivo and in Vitro Assay.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- The History of Durable Left Ventricular Assist Devices and Comparison of Outcomes: HeartWare, HeartMate II, HeartMate 3, and the Future of Mechanical Circulatory Support.Journal of clinical medicine · 2022Review
- Article
- A reappraisal of the pharmacologic management of gastrointestinal bleeding in patients with continuous flow left ventricular assist devices.Heart failure reviews · 2021Review
- Angiopoietin-2 and hemocompatibility-related adverse events during percutaneous left ventricular assist device supports.Health science reports · 2020Article
- HeartWare Ventricular Assist Device Cannula Position and Hemocompatibility-Related Adverse Events.The Annals of thoracic surgery · 2020Article
- Implication of Hemodynamic Assessment during Durable Left Ventricular Assist Device Support.Medicina (Kaunas, Lithuania) · 2020Review
- Hemocompatibility-related Adverse Events Following HeartMate II Left Ventricular Assist Device Implantation between Japan and United States.Medicina (Kaunas, Lithuania) · 2020Article
- Omega-3 and hemocompatibility-related adverse events.Journal of cardiac surgery · 2020Article
- Bleeding in critical care associated with left ventricular assist devices: pathophysiology, symptoms, and management.Hematology. American Society of Hematology. Education Program · 2019Article
- Left Ventricular Assist Device as Destination Therapy: a State of the Science and Art of Long-Term Mechanical Circulatory Support.Current heart failure reports · 2019Review
- Hemostatic complications associated with ventricular assist devices.Research and practice in thrombosis and haemostasis · 2019Review
Corrections and comments
- Erratum issued
Authors and funding
17 authors at 1 institution in 1 country.
Funding
Abstract
Background Gastrointestinal bleeding (GIB) is a common complication seen in patients supported with left ventricular assist devices (LVADs) and is related to increased inflammation and angiogenesis. Omega-3 is an unsaturated fatty acid that possesses anti-inflammatory and antiangiogenic properties. This study aims to assess the prophylactic efficacy of treatment with omega-3 on the incidence of GIB in LVAD patients. Methods and Results Among consecutive 166 LVAD patients enrolled in this analysis, 30 patients (49 years old and 26 male) received 4 mg/d of omega-3 therapy for 310±87 days and 136 patients in the control group (58 years old and 98 male) were observed for 302±102 days. One-year GIB-free rate was significantly higher in the omega-3 group as compared with the control group (97% versus 73%; P=0.02). Omega-3 therapy was associated with the occurrence of GIB in both the univariate (hazard ratio, 0.12; 95% CI, 0.02-0.91; P=0.040) and multivariate Cox proportional hazard ratio analyses (hazard ratio, 0.13; 95% CI, 0.02-0.98; P=0.047). The frequency of GIB was significantly lower in the omega-3 group (0.08±0.42 versus 0.37±0.93 events/y; P=0.01), accompanied by significantly lower blood product transfusion and shorter days in the hospital. The frequency of GIB remained lower among the omega-3 group after matching for patient background characteristics (96% versus 73%, P=0.028). Conclusions LVAD patients treated with omega-3 had a significant increase in freedom from GIB. A randomized controlled study is warranted to evaluate the use of omega-3 in LVAD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.